Firsts Home

Equity & Derivatives Companies, sectors, M&A and the financial industry
Reuters ahead with Dynavax FDA news; shares soar 09.10.2009 Reuters beat the competition by eight minutes on Sept. 10 with news that U.S. regulators will allow Dynavax to develop its experimental hepatitis B vaccine. Investors had written off the product, which was placed on clinical hold 18 months ago due to safety concerns. The small biotech company`s shares almost doubled before closing up 46 percent Reuters Firsts will need at least flash player 9 to give you the full experience. The latest Flash player can be downloaded here	firsts across any industry Commodities & Energy Energy, metals, agricultural and environmental markets FX & Money Markets Macroeconomics, monetary policy, FX and money markets Politics & Risk Politics and political risk Equity & Derivatives Companies, sectors, M&A and the financial industry Fixed Income Sovereign and corporate debt, credit, and ratings firsts by region Americas View stories from this region Europe / Middle East / Africa View stories from this region Asia View stories from this region Emerging Markets View stories from this region

Equity & Derivatives

Companies, sectors, M&A and the financial industry

Reuters ahead with Dynavax FDA news; shares soar

09.10.2009

Reuters beat the competition by eight minutes on Sept. 10 with news that U.S. regulators will allow Dynavax to develop its experimental hepatitis B vaccine. Investors had written off the product, which was placed on clinical hold 18 months ago due to safety concerns. The small biotech company`s shares almost doubled before closing up 46 percent

Reuters Firsts will need at least flash player 9 to give you the full experience. The latest Flash player can be downloaded here